MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.740
+0.270
+7.78%
Opening 10:52 05/26 EDT
OPEN
3.550
PREV CLOSE
3.470
HIGH
3.740
LOW
3.530
VOLUME
36.07K
TURNOVER
97.62K
52 WEEK HIGH
16.53
52 WEEK LOW
2.850
MARKET CAP
159.85M
P/E (TTM)
-1.2594
1D
5D
1M
3M
1Y
5Y
--Goldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating
MT Newswires · 2d ago
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold...
GlobeNewswire · 3d ago
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Benzinga · 05/19 16:31
Baird Upgrades Cellectis to Outperform From Neutral
MT Newswires · 05/18 06:10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/17 12:09
BRIEF-Cellectis To Present Immune-Evasive Universal CAR T-Cell Data
reuters.com · 05/16 12:17
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will prese...
GlobeNewswire · 05/16 12:15
--Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintained
MT Newswires · 05/13 10:41
More
No Data
Learn about the latest financial forecast of CLLS. Analyze the recent business situations of Cellectis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

36.36%Strong Buy
18.18%Buy
36.36%Hold
9.09%Under-perform
0.00%Sell
Analyst Price Target
The average CLLS stock price target is 16.11 with a high estimate of 38.00 and a low estimate of 3.000.
High38.00
Average16.11
Low3.000
Current 3.770
EPS
Actual
Estimate
-0.74-0.56-0.37-0.19
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 95
Institutional Holdings: 13.59M
% Owned: 31.80%
Shares Outstanding: 42.74M
TypeInstitutionsShares
Increased
15
2.65M
New
9
343.72K
Decreased
16
410.64K
Sold Out
15
5.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Jean-Pierre Garnier
Chief Executive Officer/Co-Founder/Executive Board/Director
Andre Choulika
Deputy Chief Executive Officer/Co-Founder/Executive Vice President/Director
David Sourdive
Chief Financial Officer/Executive Board
Bing Wang
Chief Human Resource Officer/Executive Vice President/Executive Board
Kyung Nam-Wortman
Senior Vice President/Executive Board
Steven Doares
Senior Vice President
Mark Frattini
Chief Scientific Officer/Executive Board
Philippe Duchateau
Chief Compliance Officer/Executive Board
Stephan Reynier
General Counsel/Executive Board
Marie-Bleuenn Terrier
Executive Board/IR Contact Officer
Arthur Stril
Executive Board
Carrie Brownstein
Non-Executive Independent Director
Laurent Arthaud
Non-Executive Independent Director
Pierre Bastid
Non-Executive Independent Director
Rainer Boehm
Non-Executive Independent Director
Alain Godard
Non-Executive Independent Director
Herve Hoppenot
Non-Executive Independent Director
Annick Schwebig
No Data
No Data
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.